

# **Imaging the (un)imaginable of the Barrier Immune system** Guo, N.

### Citation

Guo, N. (2023, April 18). *Imaging the (un)imaginable of the Barrier Immune system*. Retrieved from https://hdl.handle.net/1887/3594146

Version:	Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/3594146

Note: To cite this publication please use the final published version (if applicable).

### Chapter 3

### Immune subset-committed proliferating cells populate the human foetal intestine throughout the second trimester of gestation

Nannan Guo<sup>1</sup>, Na Li<sup>1,2</sup>, Li Jia<sup>1</sup>, Qinyue Jiang<sup>1</sup>, Mette Schreurs<sup>1</sup>, Vincent van Unen<sup>1,3</sup>, Susana M. Chuva de Sousa Lopes<sup>4</sup>, Alexandra A. Vloemans<sup>1</sup>, Jeroen Eggermont<sup>5</sup>, Boudewijn Lelieveldt<sup>5</sup>, Frank J.T. Staal<sup>1</sup>, Noel F. C. C. de Miranda<sup>6</sup>, M. Fernanda Pascutti<sup>1</sup>\*, Frits Koning<sup>1</sup>\*

<sup>1</sup>Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands

<sup>2</sup>State Key Laboratory of Zoonotic Diseases, Institute of Zoonoses, College of Veterinary Medicine, Jilin University, Changchun, China

<sup>3</sup>Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, United States

<sup>4</sup>Department of Anatomy, Leiden University Medical Center, Leiden, The Netherlands <sup>5</sup>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands

<sup>6</sup>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands

\* Equal contribution

Nature Communications 2023, 10;14(1):1318

### Summary

The intestine harbors the largest immune compartment in the human body, yet how it is formed and organized during human fetal development is largely unknown. Here, we have analyzed a large number of human fetal intestinal samples from week 14 through week 22 of gestation. Spectral flow cytometry indicated that at week 14 of gestation, the fetal intestine was mainly populated by myeloid cells and three distinct CD3<sup>-</sup>CD7<sup>+</sup> ILCs subsets, followed by rapid appearance of adaptive CD4, CD8 T and B cell subsets in time. Ki-67<sup>+</sup> cells were observed in all identified immune subsets as early as week 14 and up to week 22. Imaging mass cytometry (IMC) confirmed the presence of Ki-67<sup>+</sup> cells in situ and identified lymphoid follicles (LFs) from week 16 onwards, which contained CD3<sup>-</sup>CD7<sup>+</sup> ILCs, T, B and myeloid cells in a villus-like structure covered by epithelium. Moreover, a proportion of CD3<sup>-</sup>CD7<sup>+</sup> ILC and T cells shared a CD69<sup>+</sup>CD117<sup>+</sup>CD161<sup>+</sup>CCR6<sup>+</sup>CD127<sup>+</sup> phenotype, resided within the LFs, and harbored Ki-67<sup>+</sup> cells. In vitro proliferation of fetal intestinal lymphoid subsets was observed both in unstimulated conditions and with IL-7. Overall, these observations demonstrate the presence of immune subset-committed cells capable of local proliferation in the developing human fetal intestine, likely contributing to the development and growth of organized immune structures throughout most of the 2<sup>nd</sup> trimester, and preparing the infant for the microbial colonization right after birth.

**Key terms:** Imaging mass cytometry, IMC, mass cytometry, CyTOF, spectral flow cytometry, human fetal intestine, proliferating cells

### Introduction

The developing human fetus generates tolerogenic and protective immune responses, in preparation for antigen exposure during pregnancy and after birth<sup>1</sup>. Multiple immune cell types develop and mature at different gestational stages, and diverse immune cells seed lymphoid and peripheral organs, including lymph nodes, skin, intestine, kidney and lung<sup>1, 2, 3</sup>. The intestine represents the largest compartment of the immune system. Immunohistochemistry (IHC) analysis of human fetal intestinal samples has shown that T cells are detectable in the lamina propria and epithelium from 12-14 weeks of gestation and T cells increase in abundance afterwards<sup>4</sup>. Moreover, evidence for co-localization of T and B cells has been presented<sup>5, 6</sup>. Nevertheless, the development and complexity of the immune compartment during human fetal life is understudied for reasons of scarcity of material and ethical concerns.

Lymphoid tissues are important locations for the initiation of adaptive immune responses<sup>7</sup>, and their formation requires interaction between lymphoid-tissue inducer cells (LTi) and stromal cells<sup>8, 9, 10</sup>. B cells also contribute to the maturation of gut-associated lymphoid tissues (GALT), including Peyer's patches (PP) and isolated lymphoid follicles (ILFs)<sup>11</sup>. In the intestinal mucosa, antigen-presenting cells (APCs) and in particular dendritic cells (DCs) are located throughout the intestinal lamina propria, and can recruit naive T cells to the different lymphoid tissues<sup>12, 13</sup>. In addition, memory CD4<sup>+</sup> T cells were frequently observed in the human fetal intestine<sup>14</sup>, and fetal intestinal TNF-a<sup>+</sup>CD4<sup>+</sup> T cells promote mucosal development<sup>15, 16</sup>.

Improvements in high-dimensional imaging and flow cytometry techniques provide new opportunities to map the niche and development of the human fetal intestinal immune compartment with higher resolution than ever before. Here we used multi-parametric spectral flow cytometry to determine the composition of the fetal immune system throughout a major part of the 2<sup>nd</sup> trimester. Furthermore, we have combined this with an imaging mass cytometry (IMC)-based approach to gain detailed insight into the spatial localization of the fetal intestinal immune system in the tissue context in time<sup>17, 18</sup>. The results indicate dynamic changes in the composition of the fetal intestinal immune system, the continuous presence of proliferation-associated Ki-67<sup>+</sup>cells in all detected immune subsets and the early formation of lymphoid follicles (LFs) harboring B cells, as well as various types of innate lymphoid cells (ILCs), T cells and myeloid cells. In addition, Ki-67<sup>+</sup> cells were frequently observed in such LFs. Moreover, we observed that subsets of CD3<sup>-</sup>

CD7<sup>+</sup> ILCs, CD4<sup>-</sup>CD8a<sup>-</sup>, CD4<sup>+</sup> and CD8a<sup>+</sup> T cells displayed a shared phenotype characterized by the expression of CD69, CD117, CD161 and CCR6 and that these cells were preferentially found in the LFs.

Together these results point very early formation of complex lymphoid structures in the human fetal intestine and suggest that local proliferation of immune subsetcommitted cells contributes to the development and growth of organized immune structures throughout most of 2<sup>nd</sup> trimester.

### Methods

### Sample processing and cell isolation

The human fetal material used in this work was obtained from elective abortions (without medical indication) with signed informed consent from all donors. The work described here was reviewed and approved by the Medical Ethical Committee of Leiden University Medical Centre (P08.087). The gestational age ranged from 14 to 22 weeks. The small intestine and colon were separated from mesentery, cut into small pieces, embedded in optimal cutting temperature compound, snap-frozen in isopentane and stored at -80 °C. The remainder of the material was used for single-cell isolation as described previously<sup>19</sup>. Briefly, after clearing of meconium, fetal intestines were cut into small fragments in a petri dish, then incubated in 15 mL 1 mM dithiothreitol (Fluka) for 10 min twice at room temperature, and then incubated with 1 mM ethylenediaminetetraacetic acid (Merck) for 1 hour twice at 37 °C under rotation to acquire intraepithelial lymphocytes (IELs). To obtain single-cell suspensions from the lamina propria, the intestines fragments were enzymatically digested with 10 U/mL collagenase IV (Worthington) and 200 µl/mL DNAseI grade II (Roche Diagnostics) in 15 mL of Hank's balanced salt solution (ThermoFisher Scientific) overnight at 37 °C. After incubation, the cell preparations were filtered through a 70  $\mu$ m cell strainer (Corning) followed by washing of the cells with Iscove's Modified Dulbecco's Medium (IMDM, Lonza). Isolated cells were then purified with a Percoll gradient (GE Healthcare). Purified cells were cryopreserved in liquid nitrogen until time of analysis in 90% FCS and 10% dimethyl sulfoxide (DMSO) (Merck). All experiments were conducted in accordance with local ethical guidelines and the principles of the Declaration of Helsinki.

### Spectral Flow cytometry immunophenotypic studies

The 26-antibody flow cytometry-based panel was developed for in-depth immunophenotyping of the major cell subsets present in the human fetal intestine

through time. In total, 3 experiments were performed for immunophenotypic studies of 28 human fetal intestinal samples. Antibodies used for spectral flow cytometry with a 5-laser Cytek® Aurora are listed in Supplementary Table 1. For surface staining, single-cell suspensions of fetal intestinal samples were incubated with fluorochrome-conjugated antibodies and human Fc block (BioLegend) for 30 min at 4 °C. After washing, cells of samples were then fixed/permeabilized using Foxp3 Staining Buffer Set, according to manufacturer's instructions (ThermoFisher). For intracellular staining, the fixed/permeabilized cells were incubated with the antibodies for 45 min at 4 °C, followed by washing of the cells with permeabilization buffer. Then the stained cells were resuspended. Reference samples were incorporated and individually stained by UltraComp eBeads<sup>™</sup> Compensation Beads (ThermoFisher), PBMCs or cells from human tonsils. After the completion of the sample preparation, the samples were immediately acquired using a 5-laser Cytek® Aurora (BD Biosciences). Data were analyzed to check quality with FlowJo software version 10.6 (Tree Star Inc). We utilized OMIQ to perform the high-dimensional analysis for human fetal intestinal samples (https:// www.omiq.ai/).

#### Imaging Mass Cytometric Immunostaining, Acquisition and Analysis

Antibodies and staining procedures used on the human fetal intestine for IMC were optimized from the antibody panel and protocol developed in a previous publication<sup>18</sup>. IMC immunostaining was performed on frozen human fetal intestine samples in three independent experiments, and antibodies used for each IMC are listed in Supplementary Table 2-4. The carrier-free formulations of antibodies were conjugated to lanthanide metals using the MaxPar Antibody Labeling Kit (Fluidigm) following the manufacturer's instructions. We dried the tissue section for 1 h at 60 ° C, followed by fixation with paraformaldehyde (PFA) for 5 min at RT, then cold methanol for 5 min at -20° C. Then, the samples were incubated with the antibody panel at 4°C overnight. Next, tissue acquisition was performed on a Helios time-of-flight mass cytometer coupled to a Hyperion Imaging System (Fluidigm). All raw data were analyzed for marker intensity based on the maximum signal threshold, defined at the 98th percentile of all pixels in a single ROI using Fluidigm MCD<sup>™</sup> viewer (v1.0.560.2).

We developed the computational tool "Cytosplore Imaging" to analyze multiple markers simultaneously to perform pixel analysis for IMC data. Cytosplore Imaging facilitates the complete exploration pipeline in an integrated manner in a ROI (Supplementary Fig. 5). Data analysis in Cytosplore Imaging included the 3

following steps: We applied the arcsin transformation with a cofactor of five upon loading the data sets (ome.TIFF files) exported from Fluidigm MCD<sup>™</sup> viewer. Next, we applied an HSNE analysis<sup>20</sup> on  $2.5 \times 10^5$  pixels from an ROI and defined the markers used for the similarity computation: CD45, D2-40, Collagen I, aSMA, CD31, E-cadherin, CD123, CD7, CD163, CD20, CD11c, CD161, Ki-67, HLA-DR, CD45RA, CD3, CD57, vimentin and CD56. Based on marker expression (Supplementary Fig. 5a), we could distinguish tissue pixels from background pixels and projected each population on the imaging viewer (Supplementary Fig. 5b). Next, we selected tissue pixels and zoomed in on these through a new HSNE analysis to visualize the structural components and identify immune cells located in the human fetal intestine (Supplementary Fig. 5c, d). Finally, we focused on CD45<sup>+/dim</sup> pixels and performed a t-SNE analysis clustering for the immune markers: CD45, CD3, CD7, CD20, HLA-DR, CD163, CD11c, CD161, CD45RA (Supplementary Fig. 75e). Using this approach, we could visualize T cells, CD3<sup>-</sup>CD7<sup>+</sup> cells, B cells, CD163<sup>+</sup> macrophages, Lin<sup>-</sup>HLA-DR<sup>+</sup> myeloid cells and E-cadherin<sup>+</sup> epithelial cells simultaneously in a single region (Fig. 3f, g).

### Cell Proliferation Assays by spectral flow cytometry

After thawing, single-cell suspensions of fetal intestinal samples were kept in a pre-warmed PBS buffer. We prepared CellTrace<sup>™</sup> Violet stock solution in 5 mM by DMSO (ThermoFisher). Cells were incubated with 2 mL of 1250 nM CellTrace<sup>™</sup> Violet dye in PBS buffer for 8 min at 37° C. Then 10 mL IMDM (Lonza) supplemented with 10% FCS was added and incubated at RT for 5 min. Next, cells were spun down at 1500 rpm for 10 min, and cells were resuspended in 6 mL pre-warmed IMDM (Lonza) supplemented with 10% FCS medium at RT for 10 min before seeding in a 96-well cell culture plate. Cells were maintained in culture medium (IMDM supplemented with 10% human serum) or in culture medium containing 25 ng/mL IL-7 (Peprotech) for 4 days. The phenotype of generated progeny as well as proliferation were determined by flow cytometry. Details on antibodies used are listed in Supplementary Table 5. After the cell surface and intracellular staining as described before, cells were acquired on a 5-laser Cytek® Aurora (BD Biosciences). Four independent experiments were performed for four fetal intestinal samples, and PBMC samples were included as a control. Data was analyzed with FlowJo software version 10.6 (Tree Star Inc).

### **TREC** analysis

DNA was extracted from fetal cells and used in a the  $\delta$ REC- $\psi$ Ja TREC analysis. 50 ng total DNA was used in qPCR experiments as described by van der Weerd et al<sup>21</sup>, using the following primers and probes on a

TagMan lightcycler: TREC  $\psi$ Ja- $\delta$ REC F:CCATGCTGACACCTCTGGTT; sj TCGTGAGAACGGTGAATGAAG; sjψJa- $\delta$ REC\_R: si TRECψJaδREC\_T:[FAM] CACGGTGATGCATAGGCACCTGC[TAM]probe; cjψJaδREC\_F:AAGCAACATCAC TCTGTGTCTAGCAC;  $cj\psi Ja - \delta REC_R$ : AATTCTGCCAAATATTACTTACTTGCTGAG; cjψJa-δREC\_T [FAM]CCAGAGGTGCGGGCCCCA[TAM] probe and genomic albumin primers/probe ALB F: TGAAACATACGTTCCCAAAGAGTTT ALB R: CTCTCCTTCTCAGAAAGTGTGCATAT; ALB T [FAM] TGCTGAAACATTCACCTTCCATGCAGA[TAM]. Data were calculated as Ct and number of divisions reported as described<sup>22</sup>.

### Cytokine production analysis by spectral Flow cytometry

After staining with CellTrace<sup>™</sup> Violet dye as described before, single-cell suspensions of fetal intestinal samples and PBMCs samples were seeded into 96-well round-bottom plates in IMDM/L-glutamine medium (Lonza) complemented with 10% human serum with or without 25 ng/mL IL-7 for 2 days at 37°C. Brefeldin A solution (10 ng/mL, Sigma-Aldrich) was added for the final 5 hours. PBMCs stimulated with anti-CD3 antiCD28 agonist antibodies (2.5 µg/ml each, BioLegend) for the final 6 hours were included as a control. The flow cytometry antibody panels were designed to detect granzyme B, IL-2, IL-17A, CD40L, IFNγ and TNF-a production in identified immune subsets at day 2 by the Cytek® Aurora (BD Biosciences). Four independent experiments were performed. Details on the flow cytometry antibodies are available in Supplementary Table 6. Data was analyzed with FlowJo software version 10.6 (Tree Star Inc). All statistics were analyzed using GraphPad Prism8 software.

### Results

## Identification of Ki-67-positive cells within all immune subsets in the developing human fetal intestine

To investigate the development of the human fetal intestinal immune compartment in time, we applied a 26-antibody flow cytometry panel to single-cell suspensions of intestinal samples from gestational weeks 14 to 22 (antibodies listed in Supplementary Table 1). We pooled the spectral flow cytometer-acquired data on CD45<sup>+</sup> immune cells of all samples (2.6 million cells) in a single analysis with optSNE.

Based on marker expression profiles (Fig. 1a), seven major immune cell populations were identified, corresponding to CD3<sup>+</sup>CD4<sup>+</sup> T cells, CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>-</sup>FoxP3<sup>+</sup> T regulatory cells (Tregs), CD3<sup>+</sup>CD8<sup>+</sup> T cells, CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup> double-negative (DN)

3

T cells, CD20<sup>+</sup>HLA-DR<sup>+</sup> B cells, CD3<sup>-</sup>CD7<sup>+</sup> ILCs and CD11c<sup>+</sup> myeloid cells (Fig. 1b, Supplementary Fig. 1-2). As we have reported previously<sup>14</sup>, we observed a dominant presence of CD4<sup>+</sup>FOXP3<sup>-</sup> conventional T cells in the fetal intestine, approximately 50% of which expressed CD161 and CD45RO while lacking CCR7 and CD45RA, indicative of a CD161<sup>+</sup> effector memory T cell type (T<sub>EM</sub>) (Fig. 1a). All CCR7<sup>-</sup>CD45RA<sup>-</sup> T<sub>EM</sub> cells were CD127<sup>+</sup> and CD69<sup>+</sup>, and differential expression of CD117 and CCR6 was observed (Fig. 1a), reflecting additional phenotypic diversity. The remainder of the CD4<sup>+</sup> conventional T cell population expressed CCR7, implying a CD45RA<sup>+</sup> naive T cell (T<sub>N</sub>) or central CD45RO<sup>+</sup> memory T cell (T<sub>CM</sub>) phenotype (Fig. 1a).

Moreover, three clusters of CD8<sup>+</sup> T cells (a. CCR7<sup>+</sup>CD8a<sup>+</sup>CD8 $\beta^+$ , b. CCR7<sup>-</sup>CD8a<sup>+</sup>CD8 $\beta^+$  and c. CD8a<sup>+</sup>CD8 $\beta^-$ ), and a single DN T cell cluster were observed (Fig. 1a, b). Also, the differential expression of CD8a, CD25, CD45RA, CD117, CD127, RORyt and CCR6 revealed the presence of three distinct subpopulations of CD3<sup>-</sup>CD7<sup>+</sup> ILCs, one of which expressed CD117, CD127 and RORyt, compatible with LTi cells (Fig. 1a, b). Two B cell clusters were present, one of which was HLA-DR<sup>+</sup>CD1c<sup>+</sup>CD45RA<sup>+</sup>CCR6<sup>+</sup>, while another was HLA-DR<sup>1</sup>ow</sup>CD1c<sup>-</sup>CD45RA<sup>1</sup>ow</sup>CCR6<sup>-</sup> (Fig. 1a, b). Finally, a single cluster of myeloid cells was observed, but differential expression of CD11c, CD163, HLA-DR, and CD1c points towards heterogeneity within this myeloid subset (Fig. 1a, b). Strikingly, we observed clusters of Ki-67-positive cells within all identified cell subsets, indicative of cell proliferation (Fig. 1b, c). Similar results were obtained in two additional independent experiments (Supplementary Fig. 1-2).

Together, these results indicated substantial heterogeneity in the developing fetal intestinal immune compartment and revealed Ki-67-positive cells in all adaptive and innate cell subsets detected.

## Stable presence of Ki-67 positive cells throughout gestational week 14 to 22

To obtain further information on the development of the fetal intestinal immune system and the presence of Ki-67 positive cells in time, we analyzed the tSNE-plots of the individual human fetal samples from gestational weeks 14 to 22 (Fig. 2a, cluster partition as shown in Fig. 1a, Supplementary Fig. 3a, b). The absolute number of CD45<sup>+</sup> cells acquired from each sample is summarized in Fig 2b while the absolute number of cells acquired for the major immune subsets in all samples is summarized in supplementary Fig. 4. At week 14, the intestinal immune compartment was primarily composed of one B cell subset, CD3<sup>-</sup>CD7<sup>+</sup> ILC subsets





and myeloid cells, followed by the rapid emergence of the other immune subsets in the weeks thereafter (Fig. 2a). The frequencies of myeloid cells and CD3<sup>-</sup> CD7<sup>+</sup> ILC steadily decreased in time (Fig. 2c, d), while the percentage of B cells, CD4<sup>+</sup> T cells, and Tregs increased in time (Fig. 2e-g), and CD8<sup>+</sup> and DN T cells remained more constant (Fig. 2h, i). From week 15 onwards, CD4<sup>+</sup> T cells were the dominant immune lineage in the intestine samples (Fig. 2f). Remarkably, we identified Ki-67<sup>+</sup> cells within all detected immune subsets at all time points (Fig. 2j, Supplementary Fig. 4c-k), while the actual percentage of Ki-67<sup>+</sup> cells within the CD45<sup>+</sup> cells remained stable in time (Fig. 2k).

Thus, while at week 14, CD3<sup>-</sup>CD7<sup>+</sup> ILC, B cells and myeloid cells are abundant in the fetal intestine, from week 15 onwards, adaptive T and B cell populations dominate the immune compartment. Moreover, stable clusters of Ki-67<sup>+</sup> cells are present in all immune lineages throughout a major part of the second trimester.

### Molecular analysis confirms peripheral expansion of intestinal T cells

T cell receptor excision circles (TREC) provide a molecular means to quantitively assess the replication history of T lymphocytes. Different TREC assays exist, which allow the measurement of extensive proliferation in the thymus (Vg-Jg TREC) or mostly peripheral expansion after thymic egress ( $\delta$ REC- $\psi$ Ja TREC). We applied the  $\delta$ REC- $\psi$ Ja TREC to fetal intestinal samples, because of its greater sensitivity to measure post thymic proliferation. Similar to earlier results in purified cord blood naive T cells, the T cells in the fetal intestine had undergone 3-4 cell divisions at week 20 and this number increased to 6.5 divisions at week 22 (Fig. 3a).

In addition we re-analyzed a previously generated single cell RNAseq dataset on purified fetal intestinal CD4<sup>+</sup> T cells<sup>14</sup>. tSNE analysis revealed a distinct cluster of CD4<sup>+</sup> T cells expressing *MKI67*, *CCNB2* and *CDK1*, in line with active proliferation (Fig. 3b). In addition these cells co-expressed *IL7R* and *CD69*, indicative of responsiveness to stimulation with IL-7 and tissue residency, respectively. Integrated analysis of the cell cycle gene expression patterns placed the *MKI67* 

**Figure 2. Presence of Ki-67**<sup>+</sup> **cells throughout gestational week 14 to 22. (a)** Display of the Ki-67 expression in the optSNE plots of the individual fetal intestinal samples from week 14 through 22. Colors represent relative expression of Ki-67. Data are representative of three independent experiments. (b) The frequency of CD45<sup>+</sup> immune cells within all human fetal intestine samples analyzed (n = 28). **(c-i)** Overview of the frequency of each immune lineage within the CD45<sup>+</sup> immune cells of all human fetal intestine samples analyzed (n = 28). **(j)** Overview of the distribution of Ki-67<sup>+</sup> cells in the indicated immune lineages from gestational week 14 through 22, the results shown are from the samples shown in panel **(a). (k)** The percentage of Ki-67<sup>+</sup> cells within the CD45<sup>+</sup> immune cells of all human fetal intestine samples analyzed (n = 28).



(Figure legend in previous page)

positive cells in the G2M phase (Fig. 3c), indicative of active proliferation. Finally, we analyzed the expression of genes associated with T cell receptor rearrangements. Expression of *RAG1* and *LIG4* were only detected in few cells while no expression of *RAG2* and *DNTT* was found (Fig. 3d), arguing against T cell receptor rearrangements taking place in the fetal intestinal compartment.

Altogether, these results point to recent or active proliferation in the intestinal T cell compartment.

## Lymphoid Follicles form early in the development of the human fetal intestine

To explore the development and spatial organization of the fetal intestinal immune system in situ, we employed imaging mass cytometry (IMC) on tissue sections of human fetal intestinal samples from different gestational ages (Fig. 4). For this we developed and optimized antibody panels that incorporated markers to distinguish tissue structure, and innate and adaptive immune subsets (Supplementary Table 2-4). Based on E-cadherin and CD45 expression patterns, the epithelium and immune cells could be readily identified (Fig. 4a). Most CD45<sup>+</sup> immune cells were localized in the lamina propria in all fetal intestine samples (Fig. 4a). Strikingly, aggregates of immune cells were present in all samples in villus-like structures covered by epithelium, termed lymphoid follicles (LFs) hereafter, which presented with a higher density of  $CD45^+$  immune cells in time (Fig. 4a, encircled by boxes). Analysis of the expression of the immune lineage markers CD3, CD7, CD20, HLA-DR and CD163 revealed the presence of T cells, CD3<sup>-</sup>CD7<sup>+</sup> ILCs, B cells and two subsets of myeloid cells within the LFs (Fig. 4b-f). At week 16 of gestation, HLA-DR<sup>+</sup> myeloid cells were the primary immune cell population in the LFs, while CD3<sup>-</sup>CD7<sup>+</sup> ILCs, B cells and a few T cells were also detected. At later time points in gestation, increased numbers of B and T cells were detected.

Further analysis indicated the expression of CD127 and CD117 by the CD3<sup>-</sup>CD7<sup>+</sup> ILCs, suggestive of an LTi-like phenotype (Supplementary Fig. 5a). Moreover, most B cells within the LFs displayed expression of CD1c (Supplementary Fig. 5b,c), while both CD11c<sup>+</sup>HLA-DR<sup>+</sup> and CD163<sup>+</sup> myeloid cells could be identified at all gestational ages investigated (Fig. 4d, e, Supplementary Fig. 5d). Together, this global analysis revealed the presence of similar immune subsets in LFs through gestational week 16 to 21, with a gradual increase in adaptive immune cells in time.

We next aimed to obtain a comprehensive overview of the organization of all



**Figure 3. T cell receptor excisions circle (TREC) and single cell RNA-seq analysis confirms peripheral expansion of intestinal T cells. (a)** Proliferative history in human fetal intestinal samples. **(b-d)** t-SNE embedding showing 1804 CD4<sup>+</sup> T cells from a human fetal intestine analyzed by single-cell RNA-sequencing. The log-transformed expression levels of indicated immune markers **(b)**, the phase of the cell-division cycle **(c)** and genes involved in TCR rearrangement **(d)** are shown. Each dot represents a single cell. The proliferative CD4<sup>+</sup> T cells are encircled **(b)**.

detected immune subsets in a single image from a 21-week sample where a large LF was visible. For this we made use of "*Cytosplore Imaging*", which was adapted from *Cytosplore*<sup>+HSNE 20</sup>, to allow analysis of the IMC data at the single-pixel level. Supplementary Fig. 6 provides an exploration workflow of "*Cytosplore Imaging*", indicating how the tissue-specific pixels are extracted from the original

3

IMC dataset, where pixels representing a single cell type are assigned a color and projected back onto the original image. The approach allows the simultaneous visualization of up to 9 cell types with unique colors in a single image at 1  $\mu$ M pixel resolution (Supplementary Fig. 6a-d).

We applied this approach to visualize the composition and organization of immune cells in the 21-week LF. For this, we embedded the CD45<sup>+/dim</sup> pixels at the data level and projected the immune subset-related pixels back onto the image. The resulting image revealed the distribution of T cells (CD3<sup>+</sup>CD7<sup>+</sup>), CD3<sup>-</sup>CD7<sup>+</sup> ILCs (CD3<sup>-</sup>CD7<sup>+</sup>), B cells (CD20<sup>+</sup>HLA-DR<sup>+</sup>), Lin<sup>-</sup>HLA-DR<sup>+</sup> myeloid cells (CD3<sup>-</sup>CD7<sup>-</sup> CD20<sup>-</sup>CD163<sup>-</sup>HLA-DR<sup>+</sup>) and CD163<sup>+</sup> macrophages (CD163<sup>+</sup>HLA-DR<sup>+</sup>) in *situ* in a single region (Fig. 4f, Supplementary Fig. 6e) while the individual cell types in the LF are shown in Fig. 4g. The overview of the image indicates the presence of a B cell follicle in close contact with CD3<sup>-</sup>CD7<sup>+</sup> ILCs and T cells in the top of the villus-like structure, while underneath a cluster of HLA-DR<sup>+</sup> and CD163<sup>+</sup> myeloid cells appeared to be present in the LF, while the CD163<sup>+</sup> myeloid cells were abundant in the lamina propria.

Together these results indicated a dynamic and distinct spatial organization of the immune compartment in LFs in the developing fetal intestine.

## A CD69<sup>+</sup>CD117<sup>+</sup>CD161<sup>+</sup>CCR6<sup>+</sup>CD127<sup>+</sup> phenotype is shared by subsets of fetal intestinal CD3<sup>-</sup>CD7<sup>+</sup> ILCs and T cells

Next we focused our analysis on CD3<sup>-</sup>CD7<sup>+</sup> ILCs, DN T cells, CD4<sup>+</sup> T and CD8<sup>+</sup> T cells in the human fetal intestine. tSNE analysis of the single-cell data revealed substantial heterogeneity in all four lymphoid cell subsets (Fig. 5a-d). As expected, a sizable proportion of CD3<sup>-</sup>CD7<sup>+</sup> ILCs expressed CD117 (Fig. 5a). In addition, CD117 expressing cells were present in all T cell subsets (DN, CD8 and CD4) (Fig. 5b-d). Moreover, most CD117<sup>+</sup> lymphoid cells were CD161<sup>+</sup>, CCR6<sup>+</sup> and CD127<sup>+</sup>, while the tissue-residency marker CD69 was only present on a subset of these cells (encircled in Fig. 5b-d). Finally, small pockets of Ki-67<sup>+</sup> cells were detectable in both CD69<sup>+</sup> (encircled in Fig. 5b-d) and CD69<sup>-</sup> (indicated by the arrow in Fig. 5b-d) counterparts of the four CD117<sup>+</sup> lymphoid cell clusters, indicative of cell proliferation.

We next determined the spatial location of  $CD69^+CD117^+CD161^+CD127^+$  ILCs and T cells within the fetal intestine by IMC. First we performed pixel analysis to specifically detect and quantify co-expression of CD161 and CD69 inside and



(Figure legend in next page)

Figure 4. Identification and visualization of the immune cell composition of LFs in human fetal intestinal samples by imaging mass cytometry. (a) Visualization of E-cadherin, aSMA, and the immune cell marker CD45 reveals the overall structure of the fetal intestinal samples from week 16 through 21 and the location of LF (indicated by boxes) within those samples. Scale bar, 200 µm. Identification of CD3<sup>+</sup>CD7<sup>+</sup> T cells (yellow) and CD3<sup>-</sup>CD7<sup>+</sup> ILCs (green) by the overlay of CD3 (red) and CD7 (green) (b); CD20<sup>+</sup> B cells (blue) (c); Lin<sup>-</sup>HLA-DR<sup>+</sup> myeloid cells (magenta) (d); CD163<sup>+</sup> macrophages (white) (e). Scale bar, 40 µm. (f) Visualization of the location of the immune subsets in a representative human fetal intestine sample from gestational week 21 by pixel analysis in "*Cytosplore imaging*". Scale bar, 100 µm. The image is representative of three independent experiments. (g) Overview of the individual immune cell populations in the LF by pixel analysis. Scale bar, 40 µm.

outside the LFs (Fig. 5e, f). Here a significantly higher proportion of CD161<sup>+</sup>CD69<sup>+</sup> double-positive pixels was present in LFs compared to a similar surface area outside the LFs (Fig. 5e, f). Moreover, simultaneous visualization of CD3, CD7, CD4, CD8a, CD161, CD69, CD117 and CD127 in a single tissue slide revealed the presence of both CD3<sup>-</sup>CD7<sup>+</sup> ILC, CD4<sup>-</sup>CD8<sup>-</sup> T cells, CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells displaying a CD69<sup>+</sup>CD117<sup>+</sup>CD161<sup>+</sup>CD127<sup>+</sup> phenotype within the lymphoid follicles (Fig. 5g).

Thus, a subset of CD3<sup>-</sup>CD7<sup>+</sup> ILC and T cells share a CD69<sup>+</sup>CD117<sup>+</sup>CD161<sup>+</sup> CCR6<sup>+</sup>CD127<sup>+</sup> phenotype, harbor cells with proliferative capacity and reside within the LFs.

### Multiple types of Ki-67<sup>+</sup> proliferating cells are identified in *situ*

To verify the presence of Ki-67<sup>+</sup> proliferating cells in each immune lineage in *situ*, we included a Ki-67-specific antibody in the IMC panel and applied it to frozen sections of human fetal intestinal samples (Supplementary Table 2-4). We observed Ki-67<sup>+</sup> cells in all human fetal intestinal samples, in both the epithelium and the lamina propria (Fig. 6a, b). Moreover, within the LFs, Ki-67<sup>+</sup> cells were also detected (Fig. 6b). Within the lamina propria, we also defined the phenotype of the Ki-67<sup>+</sup>CD45<sup>+</sup> cells by simultaneous visualization of immune lineage markers (Fig. 6b, c). This revealed the presence of Ki-67<sup>+</sup>CD4<sup>+</sup> T cells, Ki-67<sup>+</sup>CD8<sup>+</sup> T cells, Ki-67<sup>+</sup>CD3<sup>-</sup>CD7<sup>+</sup> ILCs, Ki-67<sup>+</sup>CD20<sup>+</sup> B cells, Ki-67<sup>+</sup>CD163<sup>+</sup> macrophages, and Ki-67<sup>+</sup>Lin<sup>-</sup>HLA-DR<sup>+</sup> myeloid cells in the human fetal intestine (Fig. 6c and Supplementary Fig. 7). Thus, Ki-67<sup>+</sup> cells were identified in all major immune lineages in the developing fetal intestine *in situ*.

### Fetal intestinal immune subsets display proliferation potential ex vivo

Since we identified proliferation-associated Ki-67<sup>+</sup> cells across all immune cell types, we next aimed to determine if spontaneous proliferation could be detected



(Figure legend in next page)

Figure 5. Subsets of T cells and ILCs display a highly similar CD69+CD161+CD117+CCR6+CD127+ phenotype. (a-d) tSNE analysis of the CD3-CD7+ ILCs cells ( $2.4 \times 10^5$  cells), CD4<sup>-</sup>CD8<sup>-</sup> T cells ( $1.9 \times 10^5$  cells), CD4<sup>+</sup> T cells ( $1.2 \times 10^6$ ) and CD8<sup>+</sup> T cells  $(3.1 \times 10^5$  cells) from 12 human fetal intestinal samples from gestational week 14 through 22. Colors represent the relative expression of the indicated immune markers. CD69+CD161+CD117+CCR6+CD127+ cells are encircled, while their CD69- counterparts are indicated by arrows. (e) CD161<sup>+</sup>CD69<sup>+</sup> immune cells (green) and epithelium (pink) were visualized by pixel analysis in the human fetal intestine from different gestational ages. LFs are boxed by dashed lines, while similar area's devoid of LFs (non-LFs) are boxed by solid line. Scale bar, 200 µm. (f) CD161+CD69+ pixels were quantified within LFs (n = 7) and non-LF (n = 5). Error bars indicate mean  $\pm$  s.e.m. \*\* P < 0.01, Mann-Whitney test for comparisons. (g) The combination of the immune cell markers indicated was used to visualize CD69<sup>+</sup>CD161<sup>+</sup>CD117<sup>+</sup>CD127<sup>+</sup> CD3<sup>-</sup>CD7<sup>+</sup> ILC (indicated by arrow 1), CD69+CD161+CD117+CD127+ CD4-CD8- T cell (arrow 2), CD69+CD161+CD117+CD127+ CD4<sup>+</sup> T cell (arrow 3) and CD69<sup>+</sup>CD161<sup>+</sup>CD117<sup>+</sup>CD127<sup>+</sup>CD8<sup>+</sup> T cell (arrow 4) in the LF of a human fetal intestinal sample in situ. Scale bar, 50 µm.

in fetal intestinal cells when cultured *in vitro*. For this purpose, proliferation assays were performed based on CellTrace<sup>™</sup> Violet dye dilution by culturing immune cells isolated from a fetal intestinal sample in medium alone.

In addition, as we observed the prominent expression of the IL-7 receptor (CD127) by most fetal immune cell subsets (Fig. 1a), we also assessed proliferation in the presence of IL-7 for four days. Adult peripheral blood mononuclear cells (PBMCs) were used as a control. To analyze the cell cultures, we used a spectral flow cytometry antibody panel designed to discriminate B cells, CD3<sup>-</sup>CD7<sup>+</sup> ILCs, DN T cells, CD8<sup>+</sup> T cells, and CD4<sup>+</sup> T cells (including CD25<sup>+</sup> Treg-like, CD117<sup>-</sup>CD161<sup>+</sup> and CD117<sup>+</sup>CD161<sup>+</sup> subsets).

All subsets were identified in both culture conditions (Fig. 7a), indicating the presence of stable immune phenotypes in time. In the absence of IL-7, the dilution of CellTrace<sup>™</sup> Violet dye revealed cellular division accompanied by the expression of Ki-67 in all fetal intestinal immune subsets that was significantly enhanced by the addition of IL-7 (Fig. 7b). In contrast, proliferation was hardly observed in the cultures of the PBMC sample (Fig. 7c, Supplementary Fig. 8). Similar analysis

**Figure 6. Visualization of Ki-67 expression** *in situ.* (a) Visualization of Ki-67<sup>+</sup>CD45<sup>+</sup> cells in a LF by overlay of Ki-67 and CD45 on a representative human fetal intestinal sample from gestational week 21. Scale bar, 200 µm. (b) Visualization of Ki-67<sup>+</sup>CD45<sup>+</sup> cells in the lamina propria by overlay of Ki-67 and CD45 on an additional human fetal intestinal sample from gestational week 21. Scale bar, 200 µm. (c) The combination of Ki-67 and immune cell markers was used to visualize (a1 and b1) Ki-67<sup>+</sup>CD4<sup>+</sup> T cells, (a2 and b2) Ki-67<sup>+</sup>CD8<sup>+</sup> T cells, (b3) Ki-67<sup>+</sup>CD3<sup>-</sup>CD7<sup>+</sup> ILCs, (b4) Ki-67<sup>+</sup>CD20<sup>+</sup> B cells, (b5) Ki-67<sup>+</sup>CD163<sup>+</sup> macrophage, and (b6) Ki-67<sup>+</sup>Lin<sup>-</sup>HLA-DR<sup>+</sup> myeloid cells in human fetal intestinal samples as indicated by white arrows. Scale bar, 20 µm.



(Figure legend in previous page)

of fetal immune cells from samples of gestational weeks 18, 20 and 21 likewise revealed spontaneous proliferation of fetal intestinal immune subsets that was enhanced in the presence of IL-7 (Fig. 7d).

To determine functional characteristics of the cultured fetal intestinal immune cells, we analyzed the expression of CD40L, granzyme B, TNF-a, IFNY, IL-2 and IL-17A by flow cytometry (Supplementary Fig. 9). In both the presence and absence of IL-7, a substantial proportion of CD3<sup>-</sup>CD7<sup>+</sup> ILCs, DN T cells and CD4<sup>+</sup> T cells expressed CD40L after 48 hours of culture, while this was much lower on CD8<sup>+</sup> T cells (Supplementary Fig. 9). Granzyme B was detected in CD3<sup>-</sup>CD7<sup>+</sup> ILCs, DN T cells and CD8<sup>+</sup> T cells, while intracellular levels of TNF-a, IFNY, IL-2 and IL-17A were low in all cell populations in both culture conditions (Supplementary Fig. 9). Furthermore, in the presence of IL-7 the median fluorescence intensities (MFI) of CD40L expression increased substantially in CD3<sup>-</sup>CD7<sup>+</sup> ILCs, DN T cells and CD4<sup>+</sup> T cells (Fig. 7e). Moreover, higher frequencies of CD40L<sup>+</sup>granzyme B<sup>+</sup> ILCs and T cells were detected after 48 hours of culture in the presence of IL-7 (Fig. 7f).

Thus, all immune subsets in the fetal intestine contain cells that give rise to progeny *in vitro*, in particular in the presence of IL-7, which is accompanied by upregulation of CD40L and granzyme B expression.

### Discussion

The human intestine harbors a significant fraction of the body's immune cells<sup>23, 24, 25</sup> that controls local responses to the microbiota and food antigens to maintain homeostasis<sup>26</sup>. We and others have described the presence of both innate and

Figure 7. Fetal intestinal samples harbor cells with proliferative capacity in vitro. (a) Biaxial plots showing the gating strategy to identify immune subsets in a human fetal intestinal sample from gestational week 16 cultured in medium alone or medium with IL-7 for 4 days. The colored gates indicate the identified immune subsets. Data represent four independent experiments. (b) Histogram showing CellTrace<sup>™</sup> Violet dye dilution in the indicated immune subsets from the human fetal intestine. Dashed lines represent the fetal intestinal sample cultured in medium, while solid lines represents the fetal intestinal sample cultured in medium with IL-7. (c) Histogram showing CellTrace<sup>™</sup> Violet dye dilution by the indicated immune subsets from a PBMCs sample. Dashed lines represent the PBMCs cultured in medium, while solid lines represents the PBMCs cultured in medium with IL-7. (d) CTV<sup>diluted</sup> cells of the immune subset indicated from human fetal intestinal samples in both culture conditions. Data were from four independent experiments. \*P < 0.05, Mann-Whitney test for comparisons. (e) Comparison of the mean MFI values of CD40L expression between culture in medium alone and in the presence of IL-7. (f) Comparison of the percentages of CD40L<sup>+</sup>granzyme B<sup>+</sup> expressing cells within CD3<sup>-</sup>CD7<sup>+</sup> ILCs, CD4<sup>-</sup>CD8<sup>-</sup> T cells, CD4<sup>+</sup> T cells and CD8<sup>+</sup> cells in both culture conditions. Error bars indicate mean  $\pm$  s.e.m. \*P < 0.05, Wilcoxon signed-rank test for comparisons.



(Figure legend in previous page)

67

adaptive cells with complex immune phenotypes in the human fetal intestine<sup>14,</sup> <sup>15, 19, 27</sup>. Moreover, direct comparison of fetal and infantile samples has revealed substantial differences in immune composition in both the adaptive and innate compartment<sup>16</sup>. Yet little is known about the temporospatial development of the fetal intestinal immune system.

Here, we have used spectral cytometry and imaging mass cytometry (IMC) to explore the composition and distribution of immune cells in the human fetal intestine across the second trimester (14 to 22 weeks of gestation). At gestational weeks 14-15, the immune compartment was mostly composed of myeloid cells and CD3<sup>-</sup>CD7<sup>+</sup> ILCs (Fig. 1 and 2), which corresponds with observations in other fetal tissues, where these innate cell subsets appear earlier than their adaptive counterparts<sup>15</sup>. In suspension, most myeloid cells co-expressed CD11c, HLA-DR and CD45RO, with some cells expressing CD1c or CD163. IMC confirmed the abundant presence of Lin<sup>-</sup>HLA-DR<sup>+</sup> and CD163<sup>+</sup>HLA-DR<sup>-</sup> cells in different anatomical locations. While Lin-HLA-DR<sup>+</sup> cells were close to the epithelium in the lamina propria, CD163<sup>+</sup>HLA-DR<sup>-</sup> cells were found both in the LP as well as in the submucosa (Fig. 4). Previously we have provided evidence for the presence of several CD3<sup>-</sup>CD7<sup>+</sup> ILC subsets in the fetal intestine, including ILC3<sup>19</sup>. In agreement, we now observed three phenotypically distinct clusters of CD3<sup>-</sup>CD7<sup>+</sup> ILCs, one of which displayed features of ILC3/lymphoid tissue inducer cells (LTi; CD3<sup>-</sup>CD7<sup>+</sup>CD117<sup>+</sup>CD161<sup>+</sup>CCR6<sup>+</sup>CD127<sup>+</sup>RORgt<sup>+</sup>). These results are in line with a recent study in which Elmentaite et al used single cell RNA sequencing to map the cell types in the human intestine<sup>28</sup>. They reported that LTi-like NCR<sup>+</sup> and NCR<sup>-</sup> ILC3s were particularly abundant in the fetal intestine compared to both pediatric and adult samples. Moreover, these were located in proximity to CXCL13expressing lymphoid tissue organizer-like stromal cells, in line with their role in lymphoid tissue formation in the fetal gut<sup>28</sup>. It remains to be investigated how these observations match with the observed formation of lymphoid follicles in the fetal intestine in our current study. Remarkably, ILC3s in tissues from patients with Crohn's disease matched fetal NCR<sup>+</sup> ILC3s with more than 60% probability, which suggests fetal lymphoid tissue development programs could be implicated in the Crohn's disease pathogenesis<sup>28</sup>.

From 17 weeks onwards, B and T cells were the most abundant cell subsets and the composition of the fetal intestinal immune compartment remained relatively stable (Fig. 1 and 2). B cells were divided into two clusters. The most prominent of these clusters were composed of CD20<sup>+</sup>HLA-DR<sup>+</sup> B cells that co-expressed CCR6 and CD1c. In humans, CD1c is expressed by mantle zone B-cells of the tonsil, lymph node and spleen, and marginal zone B (MZB) cells of the spleen<sup>29</sup>. Recently,

high expression of CD1c was described in a population of transitional B cells that migrate to the gut and later give rise to MZB cells<sup>30</sup>. MZB cells are strategically located at the interface between the circulation and the white pulp of the spleen, providing the first line of defense by rapidly producing IgM and IgG antibodies in response to infections<sup>31</sup>. They can also be found in the subepithelial dome of intestinal Peyer's patches and produce IgM, IgG and IgA antibodies to commensal antigens<sup>31</sup>. IMC analysis of human fetal intestines revealed the accumulation of fetal CD1c<sup>+</sup> B cells in lymphoid follicles, in close contact with CD3<sup>-</sup>CD7<sup>+</sup> ILCs, T cells and HLA-DR<sup>+</sup> cells (Fig. 4 and Supplementary Fig. 5-6). As transitional B cells must migrate to the gut to give rise to mature clonally-diverse MZB<sup>32</sup>, it is thus plausible that the fetal LFs are the maturation site of fetal MZB precursors where they are in close contact with T cells and HLA-DR<sup>+</sup> myeloid cells.

We previously described that substantial heterogeneity within the CD4<sup>+</sup> T cell compartment was already present at 17 weeks<sup>14</sup>. Moreover, substantial evidence has been presented indicating that the majority of fetal intestinal CD4<sup>+</sup> T cells display a memory phenotype<sup>14, 15, 16</sup>. Likewise, fetal intestinal CD8<sup>+</sup> T cells can display a memory phenotype. It has been speculated that this points to in utero exposure to foreign antigens. In agreement, Mishara et al recently provided evidence for the presence of bacterial species in fetal samples<sup>33</sup>. However, many have argued that the detection of microbial species in such samples is caused by contamination and this debate may not easily be settled. In any case, microbial presence in the fetus is sparse at best<sup>33</sup> and may not be sufficient to explain the abundance of memory T cells in the human fetal intestine samples. Alternatively, memory formation could be triggered by exposure to proteinous and non-proteinous antigens that gain access to the amniotic fluid, possibly derived from the maternal microbiota. Our previous results indicated that memory formation is associated with several signaling pathways, including that of the T cell receptor, supporting the notion that exposure to foreign antigens is at least partly responsible for the observed memory formation<sup>14</sup>. However, our current results indicate that the memory phenotype may also be associated with the expansion of adaptive immune cells, either in the developing fetal intestine or an intermediate tissue, perhaps analogous to the thymus where the majority of double-negative and single-positive thymocytes express CD45RO and display proliferative potential. Further research will be required to explore this option. Of note, fetal mesenteric lymph nodes at 20 gestational weeks contains T cells with both naïve and memory-like phenotype<sup>34</sup>.

As observed before<sup>14</sup>, a significant proportion of CD4<sup>+</sup> T cells expressed CD161

and lacked expression of CCR7, and a similar pattern was observed for CD3<sup>-</sup>CD7<sup>+</sup> ILCs, DN and CD8a<sup>+</sup> T cells (Fig. 5), potentially reflecting the shared transcriptional program observed in adult human CD161<sup>+</sup> circulatory CD4<sup>+</sup>, CD8a<sup>+</sup> (including MAIT cells) and TCRqd<sup>+</sup> T cells<sup>35</sup>. Further analysis of the CD161<sup>+</sup> cell subsets revealed that two clusters of CD117+CCR6+CD127+ cells were present that either lacked or expressed CD69 within CD3<sup>-</sup>CD7<sup>+</sup> ILCs, DN, CD4<sup>+</sup> and CD8a<sup>+</sup> T cells (Fig. 5a-d). Moreover, CD3<sup>-</sup>CD7<sup>+</sup> ILCs, DN, CD4<sup>+</sup> and CD8a<sup>+</sup> T cells displaying this CD69<sup>+</sup>CD117<sup>+</sup>CCR6<sup>+</sup>CD127<sup>+</sup> phenotype were identified in LFs by IMC (Fig. 5e), and pixel analysis confirmed the enrichment of CD161<sup>+</sup>CD69<sup>+</sup> pixels in areas where LFs were present (Fig. 5f). Together, the shared phenotype of the CD69<sup>+</sup>CD117<sup>+</sup>CD161<sup>+</sup> CCR6<sup>+</sup>CD127<sup>+</sup> cells across subsets and their localization in the LF may indicate a common function in LF development, a matter that will be investigated in future studies. So far, CD161 has been associated with IFNg and IL-17A in adult CD4<sup>+</sup> T cells<sup>36</sup>, or IFNg production in adult CD4<sup>+</sup>, CD8a<sup>+</sup> and TCRgd<sup>+</sup> T cells<sup>35</sup>. Interestingly, Cosmi *et al* revealed the presence of naïve CD161<sup>+</sup>CD4<sup>+</sup> T precursor cells in cord blood and postnatal thymus, that expressed RORgt and CCR6 and could differentiate into IL-17A/IFNg-producing cells<sup>36</sup>. Such committed thymus-derived naïve CD161<sup>+</sup>CD4<sup>+</sup> T cell precursors may enter the circulation during fetal development and home to the intestine.

While the presence of Ki-67<sup>+</sup> in the human fetal intestine has been noted before, detailed analysis of fetal samples allowed us to identify stable pockets of Ki-67+ cells in all immune cell subsets throughout a major part of the second trimester. This result is compatible with sustained proliferation of immune-subset committed cells in time (Fig. 1-2 and Supplementary Fig. 1-4). Ki-67 is expressed at variable levels throughout the cell cycle, reaching its maximum during the S-M phases and decreasing via degradation in G1/G0<sup>37</sup>. High levels of Ki-67 expression, which would be detectable by IMC, suggest lack of quiescence and rapid progression through the cell cycle. This is supported by a re-analysis of our previously generated single cell RNA sequencing data<sup>14</sup> where a subset of the fetal intestinal CD4<sup>+</sup> T cells were found to co-express CCNB2, CDK1 and MKI67 (Fig. 3b), genes associated with cell cycle. Moreover, spontaneous and IL-7-induced proliferation of fetal intestinal cells were observed in vitro and IMC confirmed the presence of Ki-67<sup>+</sup> cells with different phenotypes both in LFs as well as scattered along the LP (Fig. 6). Of note, in the infant intestinal tract Ki-67<sup>+</sup> staining was only detectable within isolated LFs and the epithelium, but not in the lamina propria<sup>38</sup>. Moreover, TREC analysis showed that T cells in the fetal intestine underwent an average of 3.5 (week 14) to 6.5 (week 22) divisions (Fig. 3a). Analysis of the expression of genes involved in TCR rearrangement (RAG1, RAG2, DNTT and LIG4) revealed

that only a few cells expressed *RAG1* and *LIG4*, while *RAG2* and *DNTT* were not expressed (Fig. 3d), arguing against extrathymic T cell development in the fetal intestine.

During the second trimester, the intestine not only doubles in length<sup>39</sup>, but also villus and microvillus formation drive an even greater increase in the intestinal surface area<sup>40</sup>. Thus, immune cell colonization of the LFs and lamina propria requires an ever increasing number of immune cells. This can occur via continuous input from the fetal liver, thymus and bone marrow, and/or local proliferation. Given the constant proportion of Ki-67<sup>+</sup> cells in the fetal intestine and their presence in every immune subset throughout most of the second trimester, the most likely scenario is that fetal T cells develop in the thymus and then migrate to the periphery where they locally expand. Based on both Ki-67 expression and division history, we can envision two scenarios. In the first scenario, differentiated immune cells including T cells travel from the primary lymphoid organs to secondary lymphoid organs or intermediate tissues, where they undergo a few rounds of proliferation and then travel to the intestine. Given that Ki-67 is detectable at stable levels, the intestine would receive recently divided cells at a regular rate throughout the second trimester. In the second scenario, differentiated immune cells would reach the intestine at a regular rate during the second trimester, where they would receive local homeostatic proliferation signals and undergo a few rounds of division. In favor of the latter, we have detected local IL-7 production in the fetal intestine, both in the epithelium and the lamina propria (data not shown).

The situation of proliferating immune cells in a growing intestine could be paralleled to the filling of niches in a lymphopenic host through homeostatic proliferation, likely in the absence of antigen. It could be envisioned that as the organ grows, new stromal niches are generated that provide signals for proliferation. In support of this idea, it has been shown that the neonatal environment in mice is functionally lymphopenic, where transferred CD4<sup>+</sup> T cells undergo proliferation<sup>41</sup>. In immune-deficient hosts, lymphopenia-induced proliferation is driven by the increased availability of IL-7<sup>41, 42, 43, 44</sup>. We detected CD127 (IL-7Ra) on most fetal human lymphoid immune cells, except Tregs, B cells and some CD3<sup>-</sup>CD7<sup>+</sup> ILC subsets (Fig. 1 and Supplementary Fig. 1-3). Unlike peripheral immune cells from healthy adults, fetal cells responded to IL-7 with vigorous proliferation after four days *in vitro*. This was accompanied by upregulation of CD40L and granzyme B in CD3<sup>-</sup>CD7<sup>+</sup> ILCs, CD4<sup>+</sup> T cells, CD8ab<sup>+</sup> T cells and DN T cells, in the absence of concurrent cytokine production (Figure 7e, f, Supplementary Fig. 9). In healthy adults, IL-7-induced proliferation was found to be restricted to CD31<sup>+</sup> recent

3

thymic emigrants (RTEs)<sup>45</sup>. Fetal intestinal CD4<sup>+</sup> T cells may be RTEs, explaining their increased sensitivity towards IL-7. In mice, IL-7 is produced by stromal cells<sup>46</sup>. Further work will be required to elucidate the source of IL-7 in the human fetal intestine.

In summary, we identified a stable presence of Ki-67<sup>+</sup> cells in all major immune subsets of human fetal intestines during the second trimester, and IL-7-enhanced proliferation in *vitro*. Through IMC, we visualized the presence and development of fetal LFs throughout the second trimester and characterized the shared phenotype of CD69<sup>+</sup>CD117<sup>+</sup>CD161<sup>+</sup>CCR6<sup>+</sup>CD127<sup>+</sup> by fetal intestinal T cells and CD3<sup>-</sup>CD7<sup>+</sup> ILCs frequently located within such LFs. Overall, these observations indicate the presence of immune subset-committed cells capable of local proliferation, contributing to the population size and development of an organized immune compartment throughout the 2<sup>nd</sup> trimester in the human fetal intestine.

### Acknowledgements

We would like to thank the staff of the Center for Contraception, Abortion and Sexuality (Leiden and The Hague) for collection and provision of fetal material used in this work as well as the donors. We thank all operators in the Flow Cytometry Core Facility of the LUMC for technical assistance with measurements on Helios and Hyperion. We thank Marieke E. Ijsselsteijn for providing help and suggestions with IMC experiments. This research was supported by the China Scholarship Council (NG, NL and LJ). SMCSL was supported by Novo Nordisk Foundation (Renew NNF21CC0073729). FK was supported by BIOMAP (Bio-markers in Atopic Dermatitis and Psoriasis), a project funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 821511 and by the collaboration project TIMID (LSHM18057-SGF) financed by the PPP allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) to stimulate public-private partnerships and co-financing by health foundations that are part of the SGF.

### **Authorship Contributions**

N.G., M.F.P. and F.K. conceived the study and wrote the manuscript. N.G. performed most experiments with the help of J.L., A. A. V and N.L.. Moreover, N.G., J.L., N.L., V.v.U., F.S., N.F.C.C.d.M. analyzed the data. S.M.C.d.S.L. collected and isolated the fetal intestine material. J.E. and B.L. set up the package of Cytosplore imaging for pixel analysis. All authors discussed the results and commented on

the manuscript.

### Statistics

Results are shown as mean  $\pm$  s.e.m. The statistics tests used were Wilcoxon matched-pairs signed-ranks test, and Mann-Whitney test for comparison. P < 0.05 was considered to be statistically significant. All statistics were analyzed using GraphPad Prism8 software.

### **Reporting Summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

### Data availability

Single-cell RNA-seq data is available via Gene Expression Omnibus accession code GSE122846. The flow cytometry data are available via Flow Repository (http://flowrepository.org/id/FR-FCM-Z5MB). Imaging mass cytometry data are deposited at Mendeley Data (https://data.mendeley.com/v1/datasets/m4vr79wsjs/draft?preview=1).

### Software availability

The installer of Cytosplore Imaging and the PDF file of UserGuide are provided in https://sec.lumc.nl/mtg-viewer/imaging/win/se\_3.3.2/Cytosplore\_Imaging\_ SE\_3.3.2.zip.

#### Reference

- 1. Park, J.-E., Jardine, L., Gottgens, B., Teichmann, S.A. & Haniffa, M. Prenatal development of human immunity. *Science* **368**, 600-603 (2020).
- Holt, P.G. & Jones, C.A. The development of the immune system during pregnancy and early life. *Allergy* 55, 688-697 (2000).
- Thome, J.J.C. et al. Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues. *Nature Medicine* 22, 72-77 (2016).
- 4. Howie, D. *et al.* Extrathymic T cell differentiation in the human intestine early in life. *J Immunol* **161**, 5862-5872 (1998).
- Spencer, J., MacDonald, T., Finn, T. & Isaacson, P. The development of gut associated lymphoid tissue in the terminal ileum of fetal human intestine. *Clinical and experimental immunology* 64, 536 (1986).
- 6. Golby, S. *et al.* B cell development and proliferation of mature B cells in human fetal intestine. *Journal of leukocyte biology* **72**, 279-284 (2002).
- Fenton, T.M. *et al.* Immuné Profiling of Human Gut-Associated Lymphoid Tissue Identifies a Role for Isolated Lymphoid Follicles in Priming of Region-Specific Immunity. *Immunity* 52, 557-570. e556 (2020).
- 8. van de Pavert, S.A. & Mebius, R.E. New insights into the development of lymphoid tissues. *Nature Reviews Immunology* **10**, 664-674 (2010).
- Shikhagaie, M.M. *et al.* Neuropilin-1 Is Expressed on Lymphoid Tissue Residing LTi-like Group 3 Innate Lymphoid Cells and Associated with Ectopic Lymphoid Aggregates. *Cell Reports* 18, 1761-1773 (2017).
- Fawkner-Corbett, D. et al. Spatiotemporal analysis of human intestinal development at single-cell resolution. Cell 184, 810-826.e823 (2021).
- 11. Shen, P. & Fillatreau, S. Antibody-independent functions of B cells: a focus on cytokines. *Nature Reviews Immunology* **15**, 441-451 (2015).
- 12. Ruane, D.T. & Lavelle, E.C. The role of CD103+ dendritic cells in the intestinal mucosal immune system. *Frontiers in immunology* **2**, 25 (2011).
- Bekiaris, V., Persson, E.K. & Agace, W.W. Intestinal dendritic cells in the regulation of mucosal immunity. *Immunol Rev* 260, 86-101 (2014).
- 14. Li, N. *et al.* Memory CD4(+) T cells are generated in the human fetal intestine. *Nat Immunol* **20**, 301-312 (2019).
- 15. Schreurs, R.R.C.E. *et al.* Human Fetal TNF-a-Cytokine-Producing CD4+ Effector Memory T Cells Promote Intestinal Development and Mediate Inflammation Early in Life. *Immunity* **50**, 462-476. e468 (2019).
- 16. Stras, S.F. *et al.* Maturation of the Human Intestinal Immune System Occurs Early in Fetal Development. *Developmental Cell* **51**, 357-373.e355 (2019).
- 17. Giesen, C. *et al.* Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. *Nature Methods* **11**, 417-422 (2014).
- Guo, N. *et al.* A 34-Marker Panel for Imaging Mass Cytometric Analysis of Human Snap-Frozen Tissue. *Frontiers in Immunology* **11** (2020).
- 19. Li, N. *et al.* Mass cytometry reveals innate lymphoid cell differentiation pathways in the human fetal intestine. *J Exp Med* **215**, 1383-1396 (2018).
- 20. van Unen, V. *et al.* Visual analysis of mass cytometry data by hierarchical stochastic neighbour embedding reveals rare cell types. *Nature Communications* **8**, 1740 (2017).
- van der Weerd, K. *et al.* Combined TCRG and TCRA TREC analysis reveals increased peripheral T-lymphocyte but constant intra-thymic proliferative history upon ageing. *Mol Immunol* 53, 302-312 (2013).
- 22. Verstegen, R.H.J. *et al.* Quantification of T-Cell and B-Cell Replication History in Aging, Immunodeficiency, and Newborn Screening. *Front Immunol* **10**, 2084 (2019).
- 23. Faria, A.M. & Weiner, H.L. Oral tolerance. Immunol Rev 206, 232-259 (2005).
- 24. Mestecky, J. & McGhee, J.R. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. *Adv Immunol* **40**, 153-245 (1987).
- 25. van der Heijden, P.J., Stok, W. & Bianchi, A.T. Contribution of immunoglobulin-secreting cells in the murine small intestine to the total 'background' immunoglobulin production. *Immunology* **62**, 551-555 (1987).
- 26. Takiishi, T., Fenero, C.I.M. & Câmara, N.O.S. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. *Tissue Barriers* **5**, e1373208-e1373208 (2017).
- 27. Li, N. *et al.* Early-Life Compartmentalization of Immune Cells in Human Fetal Tissues Revealed by High-Dimensional Mass Cytometry. *Frontiers in Immunology* **10** (2019).
- 28. Elmentaite, R. *et al.* Cells of the human intestinal tract mapped across space and time. *Nature* **597**, 250-255 (2021).
- Smith, M.E., Thomas, J.A. & Bodmer, W.F. CD1c antigens are present in normal and neoplastic B-cells. J Pathol 156, 169-177 (1988).
- 30. Tull, T.J. *et al.* Human marginal zone B cell development from early T2 progenitors. *Journal of Experimental Medicine* **218** (2021).
- 31. Cerutti, A., Cols, M. & Puga, I. Marginal zone B cells: virtues of innate-like antibody-producing

lymphocytes. Nat Rev Immunol 13, 118-132 (2013).

- 32. Zhao, Y. *et al.* Spatiotemporal segregation of human marginal zone and memory B cell populations in lymphoid tissue. *Nat Commun* **9**, 3857 (2018).
- 33. Mishra, A. *et al.* Microbial exposure during early human development primes fetal immune cells. *Cell* **184**, 3394-3409.e3320 (2021).
- 34. Mold, J.E. *et al.* Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. *Science* **330**, 1695-1699 (2010).
- 35. Fergusson, J.R. *et al.* CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. *Cell Rep* **9**, 1075-1088 (2014).
- 36. Cosmi, L. *et al.* Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. *J Exp Med* **205**, 1903-1916 (2008).
- 37. Miller, I. *et al.* Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence. *Cell Rep* **24**, 1105-1112.e1105 (2018).
- Gustafson, C.E. *et al.* Limited expression of APRIL and its receptors prior to intestinal IgA plasma cell development during human infancy. *Mucosal Immunol* 7, 467-477 (2014).
- 39. FitzSimmons, J., Chinn, A. & Shepard, T.H. Normal length of the human fetal gastrointestinal tract. *Pediatr Pathol* **8**, 633-641 (1988).
- 40. Neu, J. & Koldovsky, O. Nutrient absorption in the preterm neonate. *Clin Perinatol* **23**, 229-243 (1996).
- 41. Min, B. *et al.* Neonates support lymphopenia-induced proliferation. *Immunity* **18**, 131-140 (2003).
- 42. Surh, C.D. & Sprent, J. Homeostasis of naive and memory T cells. *Immunity* **29**, 848-862 (2008).
- 43. Fry, T.J. & Mackall, C.L. Interleukin-7: master regulator of peripheral T-cell homeostasis? *Trends Immunol* **22**, 564-571 (2001).
- 44. Guimond, M. *et al.* Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. *Nat Immunol* **10**, 149-157 (2009).
- 45. Silva, S.L. *et al.* IL-7-Induced Proliferation of Human Naive CD4 T-Cells Relies on Continued Thymic Activity. *Front Immunol* **8**, 20 (2017).
- 46. Martin, C.E. *et al.* Interleukin-7 Availability Is Maintained by a Hematopoietic Cytokine Sink Comprising Innate Lymphoid Cells and T Cells. *Immunity* **47**, 171-182.e174 (2017).





#### **Supplementary information**

Supplementary Figure. 1 Identification of Ki-67<sup>+</sup> cells within all immune subsets in the human fetal intestine. (a) A collective optSNE was performed on CD45<sup>+</sup> immune cells from 7 human fetal intestinal samples in a second experiment. Each dot represents a single cell. In total,  $5 \times 10^5$  CD45<sup>+</sup> immune cells were analyzed by OMIQ. Colors represent relative expression of indicated immune markers. (b) Based on the relative marker expression profile, each immune lineage was identified and color-coded. (c) Display of the Ki-67 expression within the CD45<sup>+</sup> immune cells. Colors represent relative expression of Ki-67.



Supplementary Figure. 2 Identification of Ki-67<sup>+</sup> cells within all immune subsets in the human fetal intestine. (a) A collective optSNE was performed on CD45<sup>+</sup> immune cells from 12 human fetal intestinal samples in a third experiment. Each dot represents a single cell. In total,  $1.02 \times 10^6$  CD45<sup>+</sup> immune cells were analyzed by OMIQ. Colors represent relative expression of indicated immune markers. (b) Based on the relative marker expression profile, each immune lineage was identified and color-coded. (c) Display of the Ki-67 expression within the CD45<sup>+</sup> immune cells. Colors represent relative expression of Ki-67.



(Figure legend in next page)

Immune subset-committed proliferating cells populate the human foetal intestine throughout the second trimester of gestation

**Supplementary Figure. 3 Presence of Ki-67**<sup>+</sup> **cells throughout gestational week 14 to 22.** The presence of Ki-67<sup>+</sup> cells in fetal intestinal samples from gestational week 14 through 22 was analyzed in two additional experiments. **(a)** Display of the Ki-67 expression in the optSNE plots of the individual fetal intestinal samples (n = 9) from gestational week 14 through 22 in a second experiment. Colors represent different level of Ki-67 expression. **(b)** Display of the Ki-67 expression in the optSNE plots of the individual fetal intestinal samples (n = 7) from gestational week 14 through 22 in a third experiment. Colors represent different level of Ki-67 expression. **(c-d)** Overview of the distribution of Ki-67<sup>+</sup> cells in the indicated immune lineages from gestational week 14 through 22 in the additional two experiments. Colors indicate different immune subsets. **(e-k)** Overview of the percentages of Ki-67<sup>+</sup> cells within each immune subset in all human fetal intestine samples analyzed (n = 28).



**Supplementary Figure 4.** Overview of the total cell count per indicated immune lineage from all human fetal intestine samples analyzed (n = 28).

**Supplementary Figure. 5 Imaging mass cytometric analysis of immune subsets composition of LFs in human fetal intestine in time. (a)** Visualization of lymphoid inducer cell-like cells (LTi-like: CD3<sup>-</sup>CD7<sup>+</sup>CD127<sup>+</sup>CD117<sup>+</sup>) within LFs. The white arrow indicates the expression of CD7, CD127 and CD117 in the absence of CD3. Scale bar, 40 μm. **(b)** Identification of CD20<sup>+</sup> B cells (blue) within LFs. Scale bar, 200 μm. **(c)** Identification of CD20<sup>+</sup>CD1c<sup>+</sup> B cells (magenta) within LFs. Scale bar, 40 μm. **(d)** Identification of HLA-DR<sup>+</sup>CD11c<sup>+</sup> myeloid cells (white) within LFs. Scale bar, 40 μm. Data are from three independent experiments.



(Figure legend in previous page)



(Figure legend in next page)

Supplementary Figure. 6 The workflow of pixel analysis for IMC data by Cytosplore **imaging.** (a) An HSNE was performed on pixels from a ROI (1000  $\mu$ m  $\times$  1000  $\mu$ m) of a human fetal intestine sample. Each dot represents a pixel (1 µm2). Colors represent the relative expression of indicated markers. (b) Based on marker expression profile, the structural markers, CD45 (a) and DNA staining (not shown), the tissue pixels (colored pink) were distinguished from the non-tissue pixels (colored blue), and both were projected to the image viewer. (c) The tissue pixels were selected as indicated and a new higher resolution embedding was generated. Colors represent relative expression of indicated markers. (d) Based on marker expression profile (c), in this level, eight distinct clusters of pixels were identified and color coded. These clusters represented immune cells (CD45+/dim), 2 populations of epithelial cells (E-cadherin+Ki-67+ and E-cadherin+Ki-67-), endothelial cells (aSMA+CD31+), smooth muscle cells (aSMA+CD31-), lymphatic endothelial cells (D2-40+), neural components (CD57<sup>+</sup>CD56<sup>+/-</sup>) and extracellular matrix of the basement membrane (Collagen I+Vimentin+). (e) A further tSNE analysis of the CD45+/dim pixels identified the various immune cell clusters. Colors represent relative expression of indicated immune markers.

**Supplementary Figure. 7 Visualization of Ki-67<sup>+</sup> cells by IMC in human fetal intestine from gestational week 16. (a)** Visualization of Ki-67<sup>+</sup>CD45<sup>+</sup> cells by staining of Ki-67 and CD45. Scale bar, 200 μm. (b) The combination of Ki-67 and immune lineage markers visualized (a1) Ki-67<sup>+</sup>CD4<sup>+</sup> T cells, (a2) Ki-67<sup>+</sup>CD8<sup>+</sup> T cells, (a3) Ki-67<sup>+</sup>CD3<sup>-</sup>CD7<sup>+</sup> ILCs, (a4) Ki-67<sup>+</sup>CD163<sup>+</sup> macrophage, and (a5) Ki-67<sup>+</sup>LIn<sup>-</sup>HLA-DR<sup>+</sup> myeloid cells in *situ*. White arrow indicated cells of interest. Scale bar, 20 μm.







CD44



(Figure legend in previous page)

Chapter 3



Supplementary Figure. 8 Proliferation assays of Ki-67<sup>+</sup> cells in each immune subsets from the PBMCs sample. (a) Biaxial plots showing the identification of investigated immune subsets by Cytek Aurora flow cytometry in the PBMCs in medium and medium with IL-7. Colors indicate different immune subsets. (b) Biaxial plots showing expression of Ki-67 versus CellTrace<sup>™</sup> Violet dye dilution on the indicated immune subsets in the PBMCs sample cultured in medium and medium with IL-7. Colors indicate different immune subsets.



**Supplementary Figure. 9 Functional profiling of fetal intestinal cells. (a-d)** Fetal intestinal cells were cultured in the absence or presence IL-7 for 48 hours followed by flow cytometric analysis of the expression of CD40L, granzyme B, TNF-a, IFN $\gamma$ , IL-2, and IL-17A in CD3<sup>-</sup>CD7<sup>+</sup> ILCs and T cells (CD4<sup>-</sup>CD8<sup>-</sup> T, CD4<sup>+</sup> T and CD8<sup>+</sup> T). In total, four independent experiments were performed. **(e)** Intracellular expression of granzyme B and CD40L was determined for CD3<sup>-</sup>CD7<sup>+</sup> ILCs and T cells (CD4<sup>-</sup>CD8<sup>-</sup> T, CD4<sup>+</sup> T and CD8<sup>+</sup> T) by flow cytometry in both culture conditions. The biaxial plots show data from one representative experiment.

### Supplementary Tables

Supplementary Table 1 Single-cell suspension spectral flow cytometry antibody panel.

	Antigen	Tag	Clone	Supplier	Cat.	Dilution
1	CCR6	BB700	11A9	BD	566478	40
2	CCR7	Spark NIR 685	G043H7	Biolegend	353257	25
3	CD117	VioBright 515	REA787	MACS	130-111-674	200
4	CD11c	PE/Cy7	3.9	Biolegend	301608	100
5	CD127	BV711	A019D5	Biolegend	351327	25
6	CD161	BUV563	HP-3G10	BD	749223	25
7	CD163	BV650	GHI/61	BD	563888	25
8	CD1c	SB436	L161	Invitrogen	62-0015-41	25
9	CD20	BV805	2H7	BD	612906	50
10	CD25	BV421	BC96	Biolegend	302630	50
11	CD3	BV510	UCHT1	Biolegend	300448	100
12	CD34	PE/CF594	581	BD	562383	50
13	CD4	CF568	SK3	CyTek	R7-20041	200
14	CD45	QD800	HI30	Invitrogen	Q10156	100
15	CD45R0	BV570	UCHL1	Biolegend	304225	200
16	CD45RA	PerCP	HI100	Biolegend	304155	200
17	CD69	APC/R700	FN50	BD	565155	50
18	CD7	BUV395	M-T701	BD	565979	100
19	CD8a	Spark Blue 550	SK1	Biolegend	344759	200
20	CD8b	BUV496	2ST8.5H7	BD	749837	200
21	FoxP3	APC	PCH101	Invitrogen	17-4776-42	25
22	HLA-DR	BV480	G46-6	BD	566154	200
23	Ki67	BV605	Ki-67	Biolegend	350521	25
24	RORgt	PE	Q21-559	BD	563081	25
25	Viability	L/D near IR	-	Invitrogen	L34976	1000
26	FC Block	-	-	Biolegend	422302	20

**Supplementary Table 2** Imaging mass cytometry antibody panel on human fetal intestine from gestational week 21.

	Antigen	Tag	Clone	Supplier	Cat.	Dilution		
1	CD45	89Y	HI30	FLM	3089003B	1/50		
2	CD69	144Nd	FN50	FLM	3144018B	1/50		
3	CD4	145Nd	RPA-T4	FLM	3145001B	1/50		
4	CD8a	146Nd	RPA-T8	FLM	3146001B	1/50		
5	Collagen I	147Sm	polyclonal	Millipore	AB758	1/100		
6	a-SMA	148Nd	1A4	CST	CST 5685BF	1/200		
7	E-cadherin	150Nd	24 E 10	CST	CST 3195BF	1/50		
8	CD123	151Eu	6H6	FLM	3151001B	1/50		
9	CD7	153Eu	CD7-6B7	FLM	3153014B	1/100		
10	CD163	154Sm	GHI/61	FLM	3154007B	1/100		
11	CD103	155Gd	EPR4166	Abcam	ab221210	1/50		
12	CD122	158Gd	TU27	BioL	339015	1/25		
13	CD68	159Tb	KP1	FLM	3159035D	1/100		
14	CD5	160Gd	UCHT2	BioL	300627	1/25		
15	CD20	161Dy	H1	FLM	3161029D	1/50		
16	CD11c	162Dy	Bu15	FLM	3162005B	1/50		
17	CD45	163Dy	D9M81	CST	13917BF	1/100		
18	CD161	164Dy	HP-3G10	FLM	3164009B	1/50		
19	Ki-67	166Er	D3B5	CST	CST 9129BF	1/200		
20	CD27	167Er	0323	FLM	3167002B	1/50		
21	HLA-DR	168Er	L243	BioL	307651	1/800		
22	CD45RA	169Tm	HI100	FLM	3169008B	1/100		
23	CD3	170Er	UCHT1	FLM	3170001B	1/100		
24	CD28	171Yb	CD28.2	BioL	302937	1/50		
25	CD38	172Yb	HIT2	FLM	3172007B	1/50		
26	CD45RO	173Yb	UCHL1	BioL	304239	1/50		
27	Vimentin	175Lu	D21H3	CST	CST 5741BF	1/200		
28	CD56	176Yb	NCAM16.2	FLM	3176008B	1/100		
	Fluidiam (Flui), Cell Signaling Technology (CST) and Biolegend (BioL)							

3

**Supplementary Table 3** Imaging mass cytometry antibody panel on human fetal intestine from gestational week 21.

	Antigen	Tag	Clone	Supplier	Cat.	Dilution
1	CD45	89Y	HI30	Flui	3089003B	1/50
2	D2-40	115In	D2-40	BioL	916606	1/50
3	FOXp3	142Nd	D608R	CST	12653BF	1/50
4	CD69	144Nd	FN50	Flui	3144018B	1/50
5	CD4	145Nd	RPA-T4	Flui	3145001B	1/50
6	CD8a	146Nd	RPA-T8	Flui	3146001B	1/50
7	Collagen I	147Sm	Polyclonal	Millipore	AB758	1/100
8	a-SMA	148Nd	1A4	CST	CST5685BF	1/200
9	CD31	149Sm	8 9C2	CST	CST3528BF	1/100
10	E-Cadherin	150Nd	24 E 10	CST	CST3195BF	1/50
11	CD123	151Eu	6H6	Flui	3151001B	1/50
12	CD7	153Eu	CD7-6B7	Flui	3153014B	1/100
13	CD163	154Sm	GHI/61	Flui	3154007B	1/100
14	CD103	155Gd	EPR4166	Abcam	ab221210	1/50
15	CD127	156Gd	R34.34	Beckman	18LIQ494	1/50
16	CD122	158Gd	TU27	BioL	339015	1/25
17	CD68	159Tb	KP1	Flui	3159035D	1/200
18	CD5	160Gd	UCHT2	BioL	300627	1/25
19	CD20	161Dy	H1	Flui	3161029D	1/50
20	CD11c	162Dy	Bu15	Flui	3162005B	1/50
21	CD45	163Dy	D9M81	CST	13917BF	1/200
22	CD161	164Dy	HP-3G10	Flui	3164009B	1/50
23	CD117	165Ho	104D2	BioL	313202	1/50
24	Ki-67	166Er	D3B5	CST	CST 9129BF	1/200
25	CD27	167Er	0323	Flui	3167002B	1/50
26	HLA-DR	168Er	L243	BioL	307651	1/800
27	CD45RA	169Tm	HI100	Flui	3169008B	1/100
28	CD3	170Er	UCHT1	Flui	3170001B	1/100
29	CD28	171Yb	CD28.2	BioL	302937	1/50
30	CD38	172Yb	HIT2	Flui	3172007B	1/100
31	CD45RO	173Yb	UCHL1	BioL	304239	1/50
32	CD57	174Yb	HNK-1/Leu-7	Abcam	Ab212403	1/100
33	Vimentin	175Lu	D21H3	CST	CST5741BF	1/200
34	CD56	176Yb	NCAM16.2	Flui	3176008B	1/50
	(BioL)					

**Supplementary Table 4** Imaging mass cytometry antibody panel on human fetal intestine from gestational week 16 to 19.

	Antigen	Tag	Clone	Supplier	Cat.	Dilution			
1	CD45	89Y	HI30	Flui	3089003B	50			
2	D2-40	115In	D2-40	BioL	916606	50			
3	FOXp3	142Nd	D608R	CST	12653BF	100			
4	CD69	144Nd	FN50	Flui	3144018B	50			
5	CD4	145Nd	RPA-T4	Flui	3145001B	50			
6	CD8a	146Nd	RPA-T8	Flui	3146001B	50			
7	Collagen I	147Sm	polyclonal	Millipore	AB758	100			
8	CD34	148Nd	QBEND/10	Thermo	MA1-10202	50			
9	CD31	149Sm	8 9C2	CST	CST3528BF	100			
10	E-cadherin	150Nd	24 E 10	CST	CST 3195BF	50			
11	CD123	151Eu	6H6	Flui	3151001B	50			
12	CD141	152Sm	Phx-01	BioL	902102	50			
13	CD7	153Eu	CD7-6B7	Flui	3153014B	100			
14	CD163	154Sm	GHI/61	Flui	3154007B	100			
15	CD103	155Gd	EPR4166	Abcam	ab221210	50			
16	CD127	156Gd	R34.34	Beckman	18LIQ494	50			
17	CD68	159Tb	KP1	Flui	3159035D	200			
18	CD20	161Dy	H1	Flui	3161029D	50			
19	CD11c	162Dy	Bu15	Flui	3162005B	50			
20	CD11c	162Dy	S-HCL-3	BioL	125602	50			
21	CD161	164Dy	HP-3G10	Flui	3164009B	50			
22	CD117	165Ho	104D2	BioL	313202	50			
23	Ki-67	166Er	D3B5	CST	CST 9129BF	200			
24	CD27	167Er	0323	Flui	3167002B	50			
25	HLA-DR	168Er	L243	BIoL	307651	800			
26	CD45RA	169Tm	HI100	Flui	3169008B	100			
27	CD3	170Er	UCHT1	Flui	3170001B	100			
28	CD1c	171Yb	L161	BioL	331501	50			
29	CD38	172Yb	HIT2	Flui	3172007B	100			
30	CD45RO	173Yb	UCHL1	BioL	304239	50			
31	CD57	174Yb	HNK-1/Leu-7	Abcam	Ab212403	100			
32	CD25	175Lu	24204.0	Thermo	MA5-23714	50			
33	CD56	176Yb	NCAM16.2	Thermo	MA1-06801	50			
34	a-SMA	194Pt	1A4	CST	56856BF	100			
35	Vimentin	198Pt	D21H3	CST	5741BF	100			
	Fluidigm (Flui), Cell Signaling Technology (CST) and Biolegend (BioL)								



	Antigen	Tag	Clone	Supplier	Cat.	Dilution
1	CD117	VioBright 515	REA787	MACS	130-111-674	200
2	CD11c	PE/Cy7	3.9	Biolegend	301608	100
3	CD127	BV711	A019D5	Biolegend	351327	25
4	CD161	BUV563	HP-3G10	BD Biosciences	749223	25
5	CD20	BUV805	2H7	BD Biosciences	612906	50
6	CD25	BV421	BC96	Biolegend	302630	50
7	CD3	BV510	UCHT1	Biolegend	300448	100
8	CD4	BUV661	SK3	BD Biosciences	612962	100
9	CD45	NovaBlue 610	2D1	Invitrogen	H005T02B05	50
10	CD7	BUV395	M-T701	BD Biosciences	565979	100
11	CD8a	SB550	SK1	Biolegend	344759	200
12	CD8b	BUV496	2ST8.5H7	BD Biosciences	749837	200
13	HLA-DR	BV750	L243	Biolegend	307671	50
14	Ki67	R718	B56	BD Biosciences	566963	100
15	Viability	L/D near IR	-	Invitrogen	L34976	1000
16	CellTrace <sup>™</sup> Violet	CTV	-	Invitrogen	34557	4000
17	FC Block	-	-	Biolegend	422302	20

**Supplementary Table 5** The antibody panel of proliferation assays by spectrum flow cytometry.

**Supplementary Table 6** The antibody panel of functional profiles analysis by spectrum flow cytometry.

	,			· · · · · · · · · · · · · · · · · · ·		
	Antigen	Tag	Clone	Supplier	Cat.	Dilution
1	CD117	VioBright 515	REA787	MACS	130-111-674	200
2	CCR7	Spark NIR 685	G043H7	Biolegend	353257	25
3	CD127	BV711	A019D5	Biolegend	351327	25
4	CD161	BUV563	HP-3G10	BD Biosciences	749223	25
5	CD20	BUV805	2H7	BD Biosciences	612906	50
6	CD25	BV421	BC96	Biolegend	302630	50
7	CD3	BV510	UCHT1	Biolegend	300448	100
8	CD4	BUV661	SK3	BD Biosciences	612962	100
9	CD45	NovaBlue 610	2D1	Invitrogen	H005T02B05	50
10	CD7	BUV395	M-T701	BD Biosciences	565979	100
11	CD8a	SB550	SK1	Biolegend	344759	200
12	CD8b	BUV496	2ST8.5H7	BD Biosciences	749837	200
13	CD45R0	BV570	UCHL1	Biolegend	304225	200
14	CD45RA	PerCP	HI100	Biolegend	304155	200
15	HLA-DR	BV750	L243	Biolegend	307671	50
16	Ki67	BV605	Ki-67	Biolegend	350521	25
17	Helios	PerCP/eFluor710	22F6	Thermo	46-9883-42	25
18	IL-17A	PE/Dazzle <sup>™</sup> 594	BL168	Biolegend	512335	25
19	IFNg	BV750	RUO	BD Biosciences	566357	50
20	TNFa	PE/Cy7	MAb11	Thermo	25-7349-82	50
21	CD40L	PE/Cy5	24-31	Biolegend	310808	50
22	Granzyme B	R718	B56	BD Biosciences	566963	50
23	IL-2	PE	MQ1-17H12	BD Biosciences	560902	200
24	Viability	L/D near IR	-	Invitrogen	L34976	1000
25	CellTrace™	CT /		- ··	24557	1000
25	Violet	CIV	-	Invitrogen	34557	4000
26	FC Block	-	-	Biolegend	422302	20

